Hollis-Eden Pharmaceuticals presents positive preclinical data on orally active anti-inflammatory steroids developed for treatment of lung inflammation.

(From Chemical Business NewsBase - Press Release)

Hollis-Eden Pharmaceuticals Inc announced that its scientists presented data detailing the oral activity of five candidate compounds in preclinical animal models relevant to cystic fibrosis at the 29th European Cystic Fibrosis Conference being held June 15-18 in Copenhagen, Denmark. Data presented in Copenhagen highlight the significant anti-inflammatory activity discovered when each of the five candidate compounds is given orally in mouse models of lung inflammation and septic shock as judged by reduced levels of pro inflammatory cytokines such as TNF alpha and IL-6 in lung and blood. Data presented also demonstrate …